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Abstract
Background: Glucagon-like peptide 1 (GLP1) analogues are promising new treatment options for
patients with type 2 diabetes, but may have both potentially beneficial and harmful cardiovascular
effects. This may also be the case for the analogues of GLP1 for clinical use. The present study
examined the effect of treatment with Liraglutide, a long-acting GLP1 analogue, on myocardial
ischemia and reperfusion in a porcine model.
Methods: Danish Landrace Pigs (70–80 kg) were randomly assigned to Liraglutide (10 μg/kg) or
control treatment given daily for three days before ischemia-reperfusion. Ischemia was induced by
balloon occlusion of the left anterior descending artery for 40 minutes followed by 2.5 hours of
reperfusion. The primary outcome parameter was infarct size in relation to the ischemic region at
risk. Secondary endpoints were the hemodynamic parameters mean pulmonary pressure, cardiac
output, pulmonary capillary wedge pressure as measured by a Swan-Ganz catheter as well as
arterial pressure and heart rate.
Results: The infarct size in relation to ischemic risk region in the control versus the Liraglutide
group did not differ significantly: 0.46 ± 0.14 and 0.54 ± 0.12) (mean and standard deviation (SD),
p = 0.21). Heart rate was significantly higher in the Liraglutide group during the experiment, while
the other hemodynamic parameters did not differ significantly.
Conclusion: Liraglutide has a neutral effect on myocardial infarct size in a porcine ischemia-
reperfusion model.
Background
Liraglutide, a long-acting Glucagon-like peptide 1 (GLP1)
analogue, allowing once daily administration in contrast
to genuine GLP1, is a promising new treatment option for
patients with type 2 diabetes [1]. This incretin hormone
stimulates beta cell insulin secretion in a glucose-depend-
ent manner, lowers glucagon, reduces appetite and
reduces body weight, effects beneficial in type 2 diabetic
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patients [2]. Since the risk of coronary heart disease is
increased 2 to 4 times in diabetic patients [3], it is of
importance to assess if ongoing Liraglutide treatment has
any deleterious or beneficial effect on myocardium
exposed to ischemia. Especially because effects of GLP1
has been reported in other organs than the pancreatic
islets, e.g. the heart [4].
Reports exist evaluating cardiac effects of GLP1 in rodents
[5-7] as well as a study in a porcine model giving GLP1 as
short-term infusions [8]. Some of these studies report
beneficial effects in myocardial ischemia-reperfusion
injury using genuine GLP1. A recent study reports similar
effects with a GLP1 analogue in an isolated rat heart
model [9]. Furthermore a recent study in mice reports
benefical effects by Liraglutide administration for 7 days
before myocardial ischemia [10]. However, few data on
the analogue Liraglutide in larger animals exists and with
clinical relevant administration of Liraglutide by subcuta-
neous injections. A recent study with another GLP1 ana-
log Exanatide has reported beneficial effects [11]. In this
study exanatide was given after 75 min of coronary liga-
tion. Results may differ in relation to timing of treatment
intervention.
GLP1 has been reported to increase heart rate and blood
pressure [12] in experimental models, possibly by increas-
ing intracellular cAMP with receptor stimulation. Such
effects could be harmful in myocardial ischemia. The
effects may also differ slightly between GLP1 and ana-
logues such as Liraglutide. Since both potential harmful
effects such as heart rate and blood pressure increase and
beneficial effects in relation to cardiovascular effects have
been reported further studies are needed.
In the present study we assessed the effect of occlusive
myocardial ischemia and subsequent reperfusion in pigs
given subcutaneous Liraglutide daily for three days before
the ischemic insult.
Methods
The protocol for the animal experiments was performed
according to the guidelines in the Guide for the Care and
Use of Laboratory Animals and was approved by the
National Committee on Animal Research Ethics (Copen-
hagen, Denmark).
Twenty-four 6-months old pigs of mixed Danish Landrace
and Yorkshire breeds with a body weight of 70–80 kg were
used. Four animals did not enter the analysis: One animal
suffered ventricular fibrillation during the initial catheter-
isation (control animal) before index ischemia and was
excluded for this reason, and another animal was
excluded due to rupture of the PTCA balloon during the
index ischemia (Liraglutide group). One animal died dur-
ing the initial anaesthesia (Liraglutide group), without
obvious reason. Another animal was excluded due to
myocardial ischemia before the index ischemia as
detected on the vector electrographic tracing and was pre-
sumably ischemic preconditioned before the index
ischemia, as judged by vector electrocardiography and for
this reason excluded (control group). The animals were
sedated with intramuscular injections of 100 mg of mida-
zolam (1,33 mg/kg) plus 500 mg of ketamine (6,66 mg/
kg) and then by intravenous injection of 1000 mg pento-
barbital. The anesthesia was maintained by intravenous
infusion of 900 mg/hour pentobarbital. After intubation,
the animals were ventilated on a respirator (Elema-Sie-
mens, Solna, Sweden) using 8.5 L/min air/oxygen (50%/
50%), adjusted according to arterial blood gas analysis
repeatedly during the experiment (ABL Radiometer A/S,
Denmark). Potassium-glucose (20 mmol potassium/500
ml glucose 5%) infusion at 50 ml/h, was infused through-
out the experiment. With this infusion rate, blood glucose
was kept in physiological ranges equally in both groups.
Rectal temperature and electrolytes were maintained in
physiological ranges in the two groups during the experi-
ment. All animals received 500 ml/h isotonic NaCl infu-
sion throughout the entire study to maintain
normovolaemia (to meet the estimated fluid require-
ments for pigs of the given size during ventilator treat-
ment).
Dosing of Liraglutide/vehicle
Liraglutide (supplied by Novo-Nordisk A/S, Denmark)
was given from 3 days before the occlusion of the coro-
nary artery. 10 microg/kg was injected subcutaneously
once daily based on suggested dose for patients with type
2 DM and resulted in comparable concentration intervals
to a previous study in humans [13]. Plasma samples (in
EDTA) for Liraglutide measurement were taken just before
coronary occlusion and measured by Novo-Nordisk, Den-
mark using a two side immunoassay method [13].
Experimental protocol
The experiment was performed in a randomised manner
with the investigators blinded to the treatment. The treat-
ment code was revealed only just before the statistical
analysis.
The right carotid artery and the neck veins were surgically
exposed and 6F introducer sheaths inserted for arterial
and venous access. The rectal temperature was stabilised
between 38°C and 38.5°C by heating with blankets or
cooling with ice packs. After stabilisation, baseline values
(temperature, heart rate, arterial blood pressure and car-
diac output) were registered. Occlusive ischemia was
induced after the stabilisation period for 40 minutes by
inflation of a conventional angioplasty balloon in the left
anterior descending coronary artery (LAD) after the 2ndBMC Cardiovascular Disorders 2009, 9:31 http://www.biomedcentral.com/1471-2261/9/31
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diagonal branch. The correct position of the balloon was
controlled by angiography immediately after balloon
inflation and just prior to balloon deflation. After balloon
deflation, a final angiogram was performed to ensure res-
toration of coronary flow. After 2.5 h of reperfusion, tho-
racothomy was performed to excise the heart after
demarcation of the ischemic region at risk.
Vector-electrocardiography
Automatic computerized Vector-electrocardiography
(Midas, Ortivus, Täby, Sweden) was used to monitor the
magnitude of ST vector deviations during the entire proce-
dure [14]. We thereby had an effective control of persist-
ent occlusion during ischemia and reperfusion and
procedure-related unwanted ischemic complications
would therefore be readily detected. During the run-in
period, the baseline ST vector magnitude was measured
during the 5 minutes prior to the angioplasty balloon
deployment.
Arrhythmia Surveillance
Monitoring was performed by a 2-channel tape recorder
(Tracker, Reynolds, Hertford, UK). We analysed the tapes
using the Pathfinder 700 electrocardiography analysis sys-
tem (Reynolds). The numbers of episodes of ventricular
fibrillation and the time from start of ischemia to first epi-
sode of ventricular fibrillation were registered.
Hemodynamic and basic parameters
Rectal temperature was monitored continuously by a rec-
tal probe. Using the jugular vein introducer sheath, a
Swan-Ganz catheter with continuous cardiac output (CO)
monitoring (by continuous thermodilution by a thermo-
filament on the standard clinical-use Swan-Ganz catheter)
was placed in a pulmonary artery and used to measure car-
diac output (using a Edwards Vigilance monitor, Horw,
Switzerland), central venous pressure (CVP), mean pul-
monary artery pressure (PAP), and pulmonary capillary
wedge pressure (PCWP). Heart rate (HR) was measured
and blood pressure (MABP) was obtained by arterial cath-
eterisation. All parameters were measured at baseline, at
15 and 35 minutes during ischemia, and at 60 and 120
minutes of reperfusion.
Blood gas and blood glucose measurements
Arterial blood analyses (includes blood glucose) was
made immediately after sheath placement (= before glu-
cose/potassium infusion), at baseline, at the end of
ischemia, and at 60 min and 120 min of reperfusion (ABL
Radiometer A/S, Denmark).
Assessment of Infarct Size
Measurement of infarct size (IS) and area at risk (AAR)
was performed as described below. A midline sternotomy
was performed after 2.5 hours of reperfusion, followed by
ligation of the LAD just distal to the second diagonal
branch. Fluoresceine (Acros Organics, Geel, Belgium) was
injected into the left auricle for in vivo demarcation of the
myocardial AAR. After excision of the heart, the left ventri-
cle (LV) was weighed and sliced in 8 mm thick slices per-
pendicular to the LAD, placed under a Wood's lamp, and
photographed with a digital camera (Camedia 4040,
Olympus Optical Co., Tokyo, Japan). After incubation in
800 ml 2,3,5-triphenytetrazolium chloride (ICN biomed-
icals Inc., Aurora, Ohio, 1% W/V phosphate buffer solu-
tion) for 10–15 min at 37°C for demarcation of IS, the
slices were re-photographed. Using digital planimetry
(analysis 3.0, Münster, Germany) the proportions of AAR
and IS to the cut surface of each section was determined.
The mass of AAR and IS was calculated by multiplying the
mass of each section with the respective proportion.
Statistics
A to sided t-test was applied for the two group comparison
of histochemical data. The hemodynamic parameters
measured were analysed using univariate ANOVA for
repeated measurements (STATA statistical software pack-
age) with emphasis on differences in change over time
with intervention between groups. Data are presented as
mean +/- standard deviation (SD). A value of p < 0.05 was
considered statistically significant. Normal distribution of
the data was tested by the Kolmogorov-Smirnov Normal-
ity test.
Results
Myocardial infarct size
Data on infarct size (IS), area at risk (AAR) and the infarct
size in relation to the area at risk (IS/AAR) are shown in
figure 1. There was no significant differences in neither
AAR, IS nor IS/AAR.
Hemodynamic data
Results of measurements of mean arterial blood pressure
(MABP), heart rate, cardiac output and mean pulmonary
pressure are shown in figures 2, 3, 4 and 5. Liraglutide did
not affect MABP (figure 2).
Apart from changes in hemodynamic parameters attribut-
able to the ischemic insult per se (such as similar
decreases in cardiac output in the two groups during the
experiment), the only parameter differing significantly
between groups was heart rate. The level of this parameter
was generally higher in the Liraglutide group during the
entire experiment (figure 3). There was no significant dif-
ference in the evolution of this parameter during the
experiment between groups. Central venous pressure, pul-
monary capillary wedge pressure and the derived parame-
ters pulmonary vascular resistance and systemic vascular
resistance did not differ between groups (data not
shown). Neither the proportion of animals suffering ven-BMC Cardiovascular Disorders 2009, 9:31 http://www.biomedcentral.com/1471-2261/9/31
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tricular fibrillation nor the time to VF was significantly dif-
ferent between groups. During the index ischemia 3
animals in both the control group and in the Liraglutide
group suffered ventricular fibrillation and were success-
fully defibrillated with 1 or 2 DC shocks (360 J). No ani-
mals had ventricular fibrillation during reperfusion.
Liraglutide concentrations were below detection level in
control group and 6738 pM (SEM: 1224 pM) in the
treated animals measured just before coronary occlusion.
Discussion
As patients with diabetes have a significantly increased
risk of coronary heart disease including risk of myocardial
infarction [3], it is of major importance that new treat-
ment options do not increase myocardial infarct size dur-
ing ischemia or increase the risk of arrhythmia during
ischemia. Liraglutide, a long-acting GLP1 analogue, is a
promising new treatment option for patients with type 2
diabetes. There is, however currently limited data on the
cardiovascular effects of especially the GLP1 analogues.
In the present study, we examined the effect of Liraglutide
administered subcutaneously as clinically intended, in
contrast to previous experimental studies with intrave-
nous infusions immediately before, during or after
ischemia. The effect was neutral on myocardial infarct size
in our porcine model. Heart rate was the only parameter
differing significantly between the groups. This is in
accordance with a previous experimental study reporting
effects of GLP1 on heart rate [12]. Blood pressure did not
differ significantly.
The obtained plasma concentrations of Liraglutide imme-
diately before ischemia was comparable to the same body
weight adjusted doses in humans [15].
Previously it has been reported in patients given GLP1
infusion in the reperfusion phase after successful PCI
based reperfusion, that ejection fraction (EF) increased in
the treated group [16]. Whether this effect was due to ino-
tropic effects previously reported for GLP1 or a true reduc-
tion of reperfusion injury is not obvious, and
Ischemic region at risk (AAR), Infarct size (IS) and the infarct size in relation to the region at risk (IS/AAR) are shown as meas- ured by histochemistry Figure 1
Ischemic region at risk (AAR), Infarct size (IS) and the infarct size in relation to the region at risk (IS/AAR) are 
shown as measured by histochemistry. The unit on the y-axis is the proportion of either left ventricular mass (AAR, IS) 
or the IS as a proportion of the AAR. P values follow from the figure. Values are mean +/- SD.
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furthermore, the mentioned study must be interpreted
cautiously because it was a non-randomised study with 10
and 11 patients in the groups. However the effect of GLP1
on myocardial ischemia may differ depending on whether
the ischemic insult is occurring during ongoing treatment
with GLP1 (or its analogues) or whether the treatment is
instituted after the ischemic insult.
A previous porcine study with GLP1 infusion during and
just prior to ischemia reported equal infarct sizes in
treated and control groups [8]. This is in accordance with
our study on Liraglutide. A recent study in a porcine
model using Exanatide showed beneficial effects when
administered at reperfusion [11]. Both timing of treat-
ment as well as dosing regimen may thus influence the
effect as well as the specific analogue.
Studies in rodent models have shown reduction in infarct
size in animals given GLP1 in both in-vivo models and in
Langendorff-perfused rat hearts [5,6]. It is, however, well
known that results may differ considerably between ani-
mal models. Larger animal models such as pigs are prob-
ably more predictive of results in humans [17].
GLP1 has, as mentioned, been reported to possess ino-
tropic and chronotropic effects, as well as precondition-
ing-like effects [18]. Such effects are in accordance with
the reported intracellular increase in cAMP levels in cardi-
omyocytes, possibly mediating these responses. It is well
known that preischemic intermittent exposure to sym-
pathomimetic effects can act as an ischemic precondition-
ing stimulus [19,20]. However continued activation of the
sympathetic system and inotropic and chronotropic
effects, leading to increased myocardial oxygen require-
ments, are certainly not beneficial in myocardial
ischemia. The possibility therefore exists that continued
exposure to GLP1 and analogues could be potentially
harmful in myocardial ischemia. This issue is therefore
obviously very important to clarify.
Despite that heart rate was significantly larger in the
treated group, the infarct sizes did not differ significantly
and liraglutide therefore seems to be safe to use in this
respect.
We chose a dosing regimen giving injections on a daily
basis on three previous days before the ischemic insult.
The cardiovascular effects could very well be different on
such a dosage scheme compared to intravenous infusions
as in most of the previous studies. However, subcutane-
ous injections are the intended route of administration
with this GLP1 analogue. It cannot be excluded that differ-
ences could be anticipated with long-term administration.
Mean blood pressures at indicated time Figure 2
Mean blood pressures at indicated time. No significant difference in change over time between groups. No significant dif-
ference in level between groups (p = 0.07 and 0.21 resp.) #: Both control and liraglutide at 60 and 120 min significantly lower 
than compared to respective baseline values (p < 0.05). Values are mean +/- SD.
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Heart rate at indicated time Figure 3
Heart rate at indicated time. #: The heart rate level is significantly larger in liraglutide group than control group through-
out (p = 0.03) the experiment, while there is no significant difference in the change over time between groups (p = 0.21). Val-
ues are mean +/- SD.
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Cardiac output at indicated time Figure 4
Cardiac output at indicated time. No significant difference between control and liraglutide group. #: significant decline in 
values at reperfusion 60 and 120 min vs. baseline in both control and intervention groups (p < 0.05), but no difference between 
groups. Values are mean +/- SD.
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Additionally, effects may differ between GLP1 and the
analogues such as Liraglutide.
Even though we did not include a direct measure of myo-
cardial contractility, the indirect measures such as blood
pressure and cardiac output did not differ between
groups. The pigs used in the present study are non-dia-
betic animals. It is possible that diabetic subjects may dif-
fer in the response compared to healthy subjects.
However, to our knowledge no porcine model of type 2
diabetes exists, and models using streptozocin etc simu-
late type 1 diabetes, and Liraglutide treatment is not
intended for type 1 diabetes. Furthermore, rodent studies
reporting beneficial effects in myocardial ischemia-reper-
fusion injury suggests an ischemic preconditioning-like
effect of GLP1. This raises the possibility, that GLP1 ana-
logues could gain use in a broader category of patients
than diabetics, if such effects could be substantiated in
larger animal models and humans. It is therefore neces-
sary to conduct studies in both non-diabetic and diabetic
animals.
The study is an acute study with no long-term follow up.
However, since the treatment with Liraglutide was ongo-
ing before the insult and during ischemia, it would be
expected that potential effects would be manifested early.
We assessed infarct size early, but we have previously
found in the present model, that infarct size does not dif-
fer significantly when measured after 3 days [21]. Finally,
the porcine model, as compared to rodent models, may be
less sensitive for demonstrating cardioprotection. We
have, however, previously demonstrated myocardiopro-
tective effects in our porcine model [14,22].
Conclusion
The present study suggests that Liraglutide, a long-acting
GLP1 analogue, administered in a clinically relevant fash-
ion, as ongoing therapy during myocardial ischemia does
not induce cardioprotection as judged from the present
animal model. Possibly Liraglutide may induce a slight
increase in heart rate as has been observed for GLP1.
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